Key Highlights

  • Paradigm Biopharmaceuticals completed enrolment in its pivotal Phase 3 PARA_OA_012 trial evaluating Zilosul (injectable pentosan polysulfate sodium) for knee osteoarthritis pain, with 538 participants enrolled across 65 sites in four countries.
  • The enrolment figure of 538 exceeds the original target of 466 participants, with the additional participants reflecting standard clinical practice for those already in screening when the target was reached.
  • An Interim Analysis remains on track for Q3 CY2026, with topline Phase 3 primary endpoint results expected in Q1 CY2027.

 

 

The completion of patient enrolment in a pivotal Phase 3 trial is one of the most operationally consequential milestones a clinical-stage pharmaceutical company can achieve. It marks the point at which the company's ability to generate the data required for regulatory submission is no longer contingent on finding and recruiting willing, eligible patients — a process that can take years and represents a dominant source of execution risk for late-stage programmes. Paradigm Biopharmaceuticals Limited (ASX:PAR) reached this point on 15 June 2026, confirming that 538 participants had commenced treatment in its PARA_OA_012 study evaluating Zilosul for the treatment of pain associated with knee osteoarthritis.

PAR shares responded positively, advancing 4.67% to A$0.16 on the announcement. The movement reflects the market attaching incremental value to the removal of enrolment execution risk from the programme's probability-adjusted outcome distribution.

Trial Design and the 538-Patient Population

PARA_OA_012 is a multicentre, randomised, double-blind, placebo-controlled Phase 3 study — the gold standard trial design for demonstrating efficacy and safety in a regulatory context. The study is being conducted across 65 clinical sites in Australia, the United States, Hong Kong, and Moldova, with the Moldova sites having been activated as part of a European expansion effort disclosed earlier in the year. The primary endpoint is the change from baseline in Weekly Average Daily Pain score at Day 112 — a 16-week treatment and assessment period — with key secondary endpoints covering physical function, patient global assessment, and responder outcomes.

The final enrolled population of 538 participants exceeds the original target of 466. The additional participants — those already undergoing screening when the enrolment target was reached — were permitted to complete the process and enrol consistent with standard ethical obligations in clinical research. This overshoot is expected to contribute to a more statistically robust dataset without altering the planned analysis framework or timelines. It may, however, marginally improve statistical power for detecting treatment effects, which is generally viewed as favourable.

Interim Analysis: The Next Critical Gating Event

Paradigm has confirmed that the previously announced Interim Analysis remains on track for Q3 CY2026. The Interim Analysis is based on the first 50% of participants reaching the Day 112 assessment milestone — a trigger that is independent of total enrolment completion. With 538 participants enrolled, the Interim Analysis pipeline is well populated, and the Q3 CY2026 timeline appears achievable absent unexpected patient dropout or assessment delays.

Interim Analyses in Phase 3 trials serve multiple functions. They provide an early signal of whether the treatment is performing as hypothesised — information that an independent Data Safety Monitoring Board can use to recommend early stopping for efficacy, early stopping for futility, or continuation to full data readout. For Paradigm, a positive or trend-supportive Interim Analysis outcome would be a major catalyst, while a futility recommendation would represent a significant setback. This binary nature makes the Q3 CY2026 Interim Analysis the most important near-term event on the PAR calendar.

The Osteoarthritis Market and Zilosul's Potential

Osteoarthritis affects more than 500 million people worldwide and represents one of the largest areas of unmet therapeutic need in medicine. The disease is the most common form of arthritis and a leading cause of disability in older populations globally. Despite its prevalence, the treatment landscape is dominated by symptom management approaches — analgesics, anti-inflammatory medications, physiotherapy, intra-articular corticosteroid or hyaluronic acid injections — rather than disease-modifying therapies. No approved disease-modifying osteoarthritis drug currently exists, a gap that regulatory agencies have acknowledged and that represents a significant commercial opportunity for any programme that successfully demonstrates structural or functional modification alongside pain relief.

Zilosul (injectable pentosan polysulfate sodium, or iPPS) has previously demonstrated statistically significant improvements in pain and function in earlier clinical studies, along with evidence suggesting favourable effects on structural and biological markers associated with OA progression. PARA_OA_012 is designed to confirm these findings in a regulatory-grade Phase 3 setting, providing the evidence base required for potential marketing approvals.

Governance Confidence and the Path to Topline Results

The completion of enrolment follows a series of prior milestones that have built incremental confidence in the programme's execution capability: a 50% dosing milestone in March 2026, the activation of Moldova sites to complete the European expansion, and an independent DSMB review of the 20% safety cohort that identified no material safety concerns. Each of these steps has proceeded on schedule, building a track record of operational delivery that is increasingly important for investors assessing whether the company can execute through to topline results.

Topline Phase 3 primary endpoint results remain on track for Q1 CY2027. If the programme delivers a statistically significant result on its primary endpoint — reduction in Weekly Average Daily Pain at Day 112 — Paradigm will have a regulatory submission package for one of the largest unmet needs in global medicine, with no approved competitor in the disease-modifying segment of the osteoarthritis treatment landscape.